Abivax Releases Additional Clinical Data on Obefazimod Safety and Effectiveness
Abivax 發布 Obefazimod 安全性與有效性的額外臨床數據
Introduction
The French biotechnology company Abivax has published new data from a Phase 3 trial for its ulcerative colitis drug, obefazimod. This news has helped the company partially recover its market value.
法國生物技術公司 Abivax 已公布其潰瘍性結腸炎藥物 Obefazimod 的第三期臨床試驗新數據。這一消息已幫助該公司部分恢復其市場價值。
Main Body
The release of this extra data follows a period of high instability in Abivax's stock price. On June 2, shares fell by about 44% after reports showed seven cases of cancer among patients taking the highest dose of the drug. However, the new data clarified that these cases were normal for the general population and were not caused by the treatment. Consequently, shares rose by 25% to 31% on Tuesday.
此次額外數據的發布是在 Abivax 股價高度不穩定的時期之後。6 月 2 日，在報告顯示服用最高劑量藥物的患者中出現 7 例癌症病例後，股價下跌了約 44%。然而，新數據澄清這些病例在一般人群中屬於正常情況，並非由治療引起。因此，股價在週二上漲了 25% 至 31%。
Regarding how well the drug works, the company reported that over 37% of patients who did not respond at first achieved clinical remission after ten months of using a 50 mg dose. This suggests that long-term use may improve results for some patients. While analysts from Jefferies described the update as positive, they emphasized that some investors might still be cautious because of the risks associated with cancer and the company's need for future funding.
關於藥效，公司報告稱，在使用 50 毫克劑量十個月後，超過 37% 最初沒有反應的患者達到了臨床緩解。這表明長期使用可能會改善部分患者的結果。儘管 Jefferies 的分析師將此次更新描述為正面，但他們強調，由於癌症相關風險以及公司對未來資金的需求，部分投資者可能仍會保持謹慎。
Strategically, Abivax plans to apply for approval from the U.S. Food and Drug Administration (FDA) in late 2026, with a planned market launch in 2027. Furthermore, the firm is expanding its research to include Crohn's disease, with a trial expected in mid-2027. Because obefazimod could become a leading treatment for inflammatory bowel disease, many believe Abivax may be bought by a larger pharmaceutical company.
在策略上，Abivax 計劃於 2026 年底向美國食品藥品監督管理局 (FDA) 申請批准，並計劃於 2027 年上市。此外，該公司正將研究擴展至克隆氏症 (Crohn's disease)，預計將於 2027 年中期進行試驗。由於 obefazimod 可能成為炎症性腸道疾病的領先療法，許多人認為 Abivax 可能會被一家更大的製藥公司收購。
Conclusion
Abivax has reduced immediate safety concerns with its new data and is staying on track for its 2026 FDA application, while remaining a likely target for acquisition.
Abivax 已透過新數據降低了即時的安全性疑慮，並維持 2026 年向 FDA 申請的進度，同時仍是可能的收購對象。
Vocabulary Learning
🚀 The 'B2 Logic' Shift: Mastering Cause and Effect
At the A2 level, you usually connect ideas with and, but, or because. To move toward B2, you need Connectors of Consequence. These words act like bridges that show a professional relationship between two events.
🔍 The Linguistic Goldmine
In the text, we see this transition clearly:
"...these cases were normal... Consequently, shares rose by 25% to 31%."
The Breakdown: Instead of saying "The data was good so the price went up," the author uses Consequently. This is a "Power Word." It tells the reader: 'Event A happened, and as a direct result, Event B occurred.'
🛠️ Upgrade Your Vocabulary
Stop using "so" for everything. Try these B2 alternatives found in or inspired by the text:
| A2 Word | B2 Upgrade | How it works |
|---|---|---|
| So | Consequently | Use this when one thing logically leads to another. |
| Also | Furthermore | Use this to add a stronger or more important point to your argument. |
| Because | Due to | Use this to link a result to a specific reason (e.g., "Due to the risks... investors are cautious"). |
💡 Pro Tip for Fluency
Notice how "Furthermore" is used in the third paragraph. It doesn't just add information; it signals that the company is growing. When you want to sound more academic or professional, start your sentence with Furthermore, followed by a comma. It gives you a second of thinking time and makes your English sound instantly more structured.